Selwyn Ho
Directeur Général chez MEDIGENE AG
Fortune : 45 062 $ au 30/04/2024
Postes actifs de Selwyn Ho
Sociétés | Poste | Début | Fin |
---|---|---|---|
MEDIGENE AG | Directeur Général | 25/07/2022 | - |
Artemis Catalyst Ltd. | Fondateur | 01/10/2017 | - |
Corporate Officer/Principal | 01/05/2019 | - | |
Immodulon Therapeutics Ltd.
Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | Directeur/Membre du Conseil | 14/06/2022 | - |
Historique de carrière de Selwyn Ho
Anciens postes connus de Selwyn Ho
Sociétés | Poste | Début | Fin |
---|---|---|---|
DERMIRA, INC. | Corporate Officer/Principal | 01/09/2016 | 01/09/2017 |
UCB | Corporate Officer/Principal | 01/03/2013 | - |
Allergan Ltd.
Allergan Ltd. Pharmaceuticals: MajorHealth Technology Allergan Ltd. provides eye care and specialty pharmaceutical products. It develops pharmaceutical products used for treatment of eye and skin care medications and neurological disorders. The firm develops products for glaucoma, dry eye, blepharospasm, cervical, dystonia, hemi-facial spasm, post-stroke spasticity and cerebral palsy. The company was founded in 1977 and is headquartered in Marlow, the United Kingdom. | Corporate Officer/Principal | - | - |
CONNECT BIOPHARMA HOLDINGS LIMITED | Corporate Officer/Principal | 01/01/2021 | - |
Formation de Selwyn Ho
Imperial College London | Undergraduate Degree |
Statistiques
Internationale
Royaume-Uni | 5 |
Chine | 2 |
Etats-Unis | 2 |
Opérationnelle
Corporate Officer/Principal | 5 |
Undergraduate Degree | 1 |
Founder | 1 |
Sectorielle
Health Technology | 7 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
CONNECT BIOPHARMA HOLDINGS LIMITED | Health Technology |
UCB | Health Technology |
MEDIGENE AG | Health Technology |
Entreprise privées | 4 |
---|---|
Dermira, Inc.
Dermira, Inc. Pharmaceuticals: MajorHealth Technology Dermira, Inc. is a biopharmaceutical company. It engages in the provision of therapies for chronic skin conditions. The company was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith on August 18, 2010 and is headquartered in Indianapolis, IN. | Health Technology |
Allergan Ltd.
Allergan Ltd. Pharmaceuticals: MajorHealth Technology Allergan Ltd. provides eye care and specialty pharmaceutical products. It develops pharmaceutical products used for treatment of eye and skin care medications and neurological disorders. The firm develops products for glaucoma, dry eye, blepharospasm, cervical, dystonia, hemi-facial spasm, post-stroke spasticity and cerebral palsy. The company was founded in 1977 and is headquartered in Marlow, the United Kingdom. | Health Technology |
Artemis Catalyst Ltd. | |
Immodulon Therapeutics Ltd.
Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | Health Technology |